Trial Profile
A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 16 May 2017 Primary endpoint (Progression-free survival rate in cohort A) has been met.
- 16 May 2017 Results published in the British Journal of Cancer
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology